Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Inclusion Criteria:

Phase 1 - Dose Escalation Phase: Advanced solid tumor that has progressed during or after treatment with approved therapies or for which there is no standard effective therapy available
Phase 2 - Dose Expansion Phase: One of the following advanced solid tumors that is RAS-mutated and has progressed during or after treatment with approved therapies or for which there is no standard effective therapy available: :
Colon Cancer with a RAS mutation
Pancreatic Cancer with a RAS mutation
Other Solid Tumor with RAS Mutation
Ocular melanoma, which includes melanoma that develops in the sclera, retina, uvea (iris, choroid layer, and ciliary layer), or conjunctiva
Glioblastoma with a RAS mutation or EGFR alteration
Phase 1 and phase 2 advanced solid tumor cohorts excluding GBM: Measurable or evaluable disease by RECIST v1.1
Phase 2 GBM only: Pathologically confirmed high-grade glioma (WHO grade 3 or 4) with a RAS mutation or altered EGFR, with documented CT or MRI progression or recurrence. Biopsy is also an acceptable method of confirming progression. If initial tumor was grade 2 glioma, histological confirmation of high-grade recurrence is required
Phase 2 GBM only: Measurable or evaluable disease by RANO (MRI) or Macdonald (CT) criteria
Phase 2 GBM only: Fixed or decreasing dose of corticosteroids (or no corticosteroids) for at least 1 week prior to cycle 1 day 1.
Phase 2 GBM only: At least 12 weeks since the completion of radiation therapy to a total of ≥ 50 Gy

All patients must meet all of the following inclusion criteria to be eligible to participate in the study:

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate bone marrow function
Absolute neutrophil count (ANC) ≥ 1500/mm3
Platelets ≥ 100,000/mm3
Hemoglobin > 9 g/dL (untransfused)
Adequate renal function
Creatinine ≤ 1.5 x upper limit of normal (ULN) for the laboratory or calculated or actual creatinine clearance ≥ 60 mL/min
Adequate hepatic function
Total bilirubin ≤ 1.5 x ULN for the laboratory Exception: If a patient has documented Gilbert's syndrome and a total bilirubin is > 1.5 x ULN for the laboratory, the total bilirubin requirement may be waived provided the direct bilirubin is within normal limits (WNL) for the laboratory.
Aspartate aminotransferase (AST) ≤ 3.0 x ULN for the laboratory
Alanine aminotransferase (ALT) ≤ 3.0 x ULN for the laboratory
Note: For the expansion cohorts, in patients with documented liver metastasis, the AST and ALT requirements will be ≤ 5 x ULN for the laboratory
Non-hematologic toxicities from previous cancer therapies resolved to ≤ grade 1 except chronic residual toxicities that in the opinion of the investigator are not clinically relevant given the known safety/toxicity profiles of neratinib and sodium valproate (eg, alopecia, changes in pigmentation, stable endocrinopathies, neuropathy, skin toxicities)
International normalized ratio (INR) is ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN for the laboratory
A woman of childbearing potential (WCBP), defined as a woman who is < 60 years of age and has not had a hysterectomy, must have a documented negative serum pregnancy test within 7 days prior to initiating study treatment
WCBP and a male patient with a partner who is a WCBP must agree to use a medically accepted method for preventing pregnancy for the duration of study treatment and for 2 months following completion of study treatment
Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

Phase 1 and phase 2 advanced solid tumor cohorts excluding GBM: Current or prior known meningeal metastases
Phase 1 and phase 2 advanced solid tumor cohorts excluding GBM: Known brain metastases that are symptomatic or untreated Note: Patients with known brain metastases who are asymptomatic and have had post-treatment imaging that indicates stable brain disease are eligible. Note that brain imaging in patients with known brain metastases is required within 8 weeks prior to initiation of study therapy.
Any investigational agent within 4 weeks prior to initiating study treatment
Previous therapy with neratinib
Active uncontrolled diarrhea leading to dehydration or electrolyte disturbances not easily controlled with oral repletion
Inability to swallow medication
Known or suspected malabsorption condition or obstruction. Note: Use of pancreatic enzyme supplements is allowed to control malabsorption
Inability to shift medications as follows: Antacids (eg, calcium carbonate): dose at least 3 hours after dosing with neratinib. H2 receptor antagonists: dose must be taken at least 2 hours after or 10 hours before dosing with neratinib
Resting systolic blood pressure (BP) < 100 mmHg
Active or clinically significant cardiac disease including any of the following:
Unstable angina (eg, anginal symptoms at rest) or onset of angina within 3 months prior to initiating study treatment
Myocardial infarction diagnosed within 6 months prior to initiating study treatment
Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers
New York Heart Association (NYHA) class III or IV congestive heart failure
Seizure disorder requiring an enzyme inducing antiepileptic medication (EIAED)
Serious (ie, ≥ grade 3) uncontrolled infection
Chronic or active hepatitis B or C infection with elevated transaminase levels
Pleural effusion or ascites that causes respiratory compromise (ie, ≥ grade 2 dyspnea)
Known mitochondrial disorder caused by mutations in mitochondrial DNA polymerase gamma (γ)
Known urea cycle disorders
Planned ongoing treatment with other drugs thought to potentially have adverse interactions with either of the medications included in the study treatment:
Cosyntropin
Proton pump inhibitors (PPIs)
High-risk P-glycoprotein (P-gp) substrates (eg, digoxin, dabigatran, fexofenadine). Other anticoagulants are not considered high-risk P-gp substrates
Strong or moderate CYP3A4 inhibitors and/or Strong or moderate CYP3A4 inducers. Examples of clinical inhibitors and clinical inducers for P450-mediated metabolism and classification of strong, moderate, and weak interactions are available through the FDA website, Tables 3-2 and 3-3: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm Note: If such medications have been used, patients must have discontinued these agents ≥ 2 weeks prior to initiating study treatment
Pregnancy or breastfeeding
Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements